Fig. 3

Adoptive transfer of MDSCs impaired antitumor effect of DIM in 4T1 tumor-bearing mice. A Representative images of tumors, B tumor volume and C tumor weight were shown after 4T1 tumor-bearing mice with the treatment of 10 mg/kg DIM (three times a week from day 8 after tumor cell inoculation) were intravenously (i.v.) injected with 5 × 10⁶ BM-derived MDSCs on day 13, 16, 19 after tumor cell inoculation (n = 8). D The percentage of total MDSCs and their subsets from bone marrow, blood, spleen and tumor was examined in DIM-treated mice after transferred with adoptive MDSCs. E Relative mRNA levels of Arg1 and iNOS in splenic MDSCs of 4T1 tumor-bearing mice co-treated with DIM and adoptive MDSC transfer. F The percentage of CD4⁺ and CD8⁺ T cells from blood, spleen and tumor was examined in DIM-treated mice after transferred with adoptive MDSCs. G IFN-γ level in tumor was measured by ELISA. Data are representative results from three independent experiments and the results are expressed as the mean ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001. T-MDSC: total MDSCs; M-MDSC: monocytic MDSC; G-MDSC: granulocytic MDSC